Entries for the current year and the preceding year are shown here. Older entries can be found in the archive.
The Treatment Selectors in the Prescribing Resources section of the website have been revised and expanded. Various new comedications have been added, along with new entries for the HIV drugs fostemsavir, oral cabotegravir and intramuscular cabotegravir/rilpivirine.
Added: Friday 22 October 2021
The single tablet regimen of rilpivirine, emtricitabine and tenofovir-DF (Eviplera®, Complera®) has been added to the list of antiretroviral drugs.
Instead of having to select the three components individually and seeing three sets of interactions, this latest update means that interactions are now combined into a single entry.
Added: Thursday 30 September 2021
Three new comedications have been added to the interaction checker. Abiraterone and avelumab are listed in the “cancer therapies” class, and calcitonin (for the prevention of bone loss) is listed in the “other” class.
Added: Tuesday 14 September 2021
Six new herbal preparations have been added to the interaction checker.
Please remember that the...
Added: Thursday 09 September 2021
Three new comedications have been added to the interaction checker. Isavuconazole (administered as its water-soluble prodrug isavuconazonium sulfate) is listed in the antifungal class. Donepezil and memantine (for the treatment of Alzheimer’s disease) are listed in the “other” class.
Added: Tuesday 07 September 2021
We have completed a review of the drugs listed in the contraceptive/HRT class of the checker to ensure that the information provided is consistent, clinically useful and up to date.
As a result of this review, HRT summaries were revised to include mention of the estrogen component (to be consistent with combined oral contraceptives) and, where required, interactions were recoded from gre...
Added: Tuesday 31 August 2021
Three new comedications have been added to the interaction checker in recent weeks. Details of the drugs and the classes in which they can be found are shown below.
Added: Thursday 12 August 2021
Dapivirine (DPV) has been added as an HIV drug in the NNRTI class. Interactions with dapivirine are available on the website checker and iChart app and will soon be added to the PDF tables of interactions. A pharmacokinetic fact sheet for dapivirine is also available in the Prescribing Resources section of t...
Added: Wednesday 21 July 2021
We are pleased to announce that our HIV drug interaction checker is now available in Spanish.
We have been working partnership with Fundación Huésped in Argentina to provide translations of the drug interaction summaries and these can now be accessed via the links on our home and checker pages, or directly from checker.huesped.org...
Added: Friday 16 July 2021
We have made some changes to the sections on our Prescribing Resources page to try to make it easier to see what resources are available. PDF files that were previously in the section “Treatment Selectors (by patient characteristics)” have been moved to one of three new sections – “Interactions Explained”, “Key Notes on …”, and “Prescribing and Dosing Guidance”.
In addition, three...
Added: Wednesday 16 June 2021
An additional HIV drug and four new comedications have been added to the interaction checker.
New HIV Drug
Enfuvirtide (Fuzeon™, ENF, T20) has been added as an HIV drug in the Entry and Attachment Inhibitors class. Enfuvirtide is a fusion inhibitor and is administered by subcutaneous injection. It has previously been listed on the checker, but only as a comedica...
Added: Wednesday 02 June 2021
Two new comedications have been added to the interaction checker and "Overview of Interactions" PDFs (in the Prescribing Resources section of the website).
Dapoxetine has been added to the "other" class and yohimbine has been added to the "erectile dysfunction" class.
Added: Tuesday 13 April 2021
Four new comedications have been added to the interaction checker - bulevirtide in the antiviral class, terbutaline in the bronchodilator class, and azilsartan and triamterene in the hypertension/heart failure class.
Added: Friday 09 April 2021
Two new comedications have been added to drug list – alirocumab (Praluent®) in the lipid lowering class and desvenlafaxine (Pristiq®) in the antidepressant class.
We have also decided to remove saquinavir from the list of HIV drugs given its very low usage worldwide.
Added: Friday 26 March 2021
A new Prescribing Resource has been added to the website which describes dose dependent enzyme induction and the clinical implications of this. Details are given for the potential dose dependent induction of six drugs - rifampicin, St John's wort, dexamethasone, phenytoin, carbamazepine, and oxcarbazepine.
Added: Monday 01 February 2021
A new Prescribing Resource has been added to the website which details the effect different types of gastric surgery can have on the absorption of antiretrovirals. Three different types of surgery are considered – bariatric surgery, small bowel resection, colonic resection – and their known and expected effects on ARV pharmacokinetics are described.
Added: Wednesday 16 December 2020
We have added some new comedications to the interaction checker and revised a few existing interactions.
Four new comedications have been added – zolmitriptan (Anti-migraine), brentuximab vedotin (Cancer therapies), enzalutamide (Cancer therapies) and polatuzumab vedotin (Cancer therapies). Cabergoline h...
Added: Monday 19 October 2020
We have completed a review of the interactions between ARVs and the single tablet regimens (STRs) used to treat HIV. Many (but not all) of the product labels for the STRs state that the STR should not be coadministered with other ARVs and for this reason such interactions were coded as red on the interaction checker. We have now reassessed all the interactions as, in specific clinical situations...
Added: Tuesday 08 September 2020
Six new comedication have been added to the interaction checker. The drugs and their classes are:
The new drugs are available on the website and the...
Added: Thursday 27 August 2020
A new HIV drug and three new comedications have been added to the interaction checker.
Fostemsavir (Rukobia®), an HIV attachment inhibitor, was recently approved by the FDA for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or sa...
Added: Tuesday 04 August 2020
Two new HIV drugs have been added to the interaction checker. Cabotegravir (oral tablets; Vocabria®) and cabotegravir/rilpivirine (extended-release injectable suspensions; Cabenuva®) have been approved for use in Canada.
For the time being, only summaries of the interactions are available. We will add full references when American and/or European product labels are available (in line wit...
Added: Thursday 02 April 2020
Integrase inhibitors can bind to polyvalent cations resulting in potentially clinically significant drug interactions with coadministered cation-containing antacids and other supplements/multivitamins. Management of such interactions often requires the temporal separation of the integrase inhibitor from the cation-containing product.
We have produced a new Prescribing Resource which give...
Added: Thursday 27 February 2020
We have renamed some of the comedications in the “Herbal/Supplements/Vitamins” class to make it clearer if possible interactions are due to the presence of multivitamins or to the comedication itself. Existing interactions have been revised to refer to when the comedication is given in a multivitamin preparation and new interactions have been added for when the comedication is given alone. The f...
Added: Tuesday 03 December 2019
Albuvirtide (Aikening®) has been added to the interaction checker on the website and is available via an update on the iChart app.
Albuvirtide is a long acting fusion inhibitor and has marketing approval in China for the treatment of HIV. Albuvirtide is administered once weekly by intravenous infusion.
Added: Wednesday 13 November 2019
Two new comedications (tazobactam and lenalidomide) have been added to the interaction checker. An update is available for the iChart app and new versions of the "Overview of Interactions" PDF files (found in Prescribing Resources) have been uploaded.
Added: Monday 04 November 2019
Six new comedications have been added to the interaction checker:
Added: Tuesday 22 October 2019
Some changes have been made to interactions with dolutegravir (Tivicay), dolutegravir/abacavir/lamivudine (Triumeq) and dolutegravir/lamivudine (Dovato) with the known enzyme/transporter inducers, rifampicin, rifapentine, carbamazepine, oxcarbazepine, eslicarbazepine, phenytoin, phenobarbitone, primidone and St John’s Wort. Summaries for these interactions have been revised and in some cases the...
Added: Monday 07 October 2019
Two dolutegravir-containing coformulations have been added to the interaction checker - Dovato® (dolutegravir and lamivudine) and Triumeq® (dolutegravir, abacavir and lamivudine).
The Overview of Interactions in the Prescribing Resources have been updated to include these coformulati...
Added: Monday 22 July 2019
Over the past few weeks we have been working on updating and expanding some of the "Prescribing and Dosing Guidance" files in the Prescribing Resources section of the website.
“Prescribing guidance for elderly PLWH” has been expanded to include two new tables – the top te...
Added: Wednesday 10 July 2019
Three new comedications have been added to the interaction checker. Ciclesonide and flunisolone are listed in the steroid class and have a lower potential to cause corticosteroid-related systemic effects compared to some other inhaled corticosteroids. Red yeast rice is a herbal preparation and contains monacolin K, a natural component with ...
Added: Tuesday 02 July 2019
Four new comedications have been added to the interaction checker and takes the total number of comedications on the website to ~730.
Added: Thursday 06 June 2019
Nine new comedications have been added to the interaction checker in response to requests received during the last 12 months or so. This takes the total number of interactions on the website to over 26,000.
Added: Tuesday 19 February 2019
Minor revisions have been made to the interaction chart for hormone therapy for gender transitioning. Three new antiretrovirals have been added to the chart - atazanavir alone, doravirine and bictegravir. The interaction chart is listed as a Treatment Selector (by patient characteristic) and can be found in the ...
Added: Friday 15 February 2019
Updated Treatment Selectors (by therapeutic indication) are now available in the Prescribing Resources section of the website.
This has been a major update as one new antiretroviral (doravirine) and four new antiretroviral combinations (atazanavir/cobicistat, darunavir/cobicistat, bictegravir/emtricitabi...
Added: Thursday 14 February 2019
A new feature has been added to the website interaction checker to make it easier to find possible alternatives when an interaction is amber or red. For these interactions, you now have the option to click on “look for alternatives”. This will take you to a new page showing interactions for the antiretroviral with other comedications in the same class.
The look for alternatives option is...
Added: Tuesday 12 February 2019
Six new comedications have been added to the interaction checker, taking the total number of comedications to nearly 720. The new comedications and their therapeutic classes are shown below:
Added: Wednesday 23 January 2019
Following on from providing two listings for darunavir according to whether it is used with cobicistat or ritonavir, we have now split atazanavir into three options.
Like darunavir, atazanavir can be used with either cobicistat or ritonavir, but in addition it is licensed in some geographical regions for use without a pharmacokinetic enhancer in certain patients.
Atazanavir now a...
Added: Tuesday 22 January 2019
Over the last few months we have been updating the list of antiretrovirals to include specific combinations and new coformulations.
Added: Tuesday 23 October 2018
Two new HIV medications have been added to the interaction checker. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and was approved by the FDA in August 2018 for the treatment of HIV-1 in combination with other antiretrovirals in adult patients with no prior antiretroviral treatment experience.
Doravirine is available as a single agent (Pifeltro®) and as a once-da...
Added: Monday 15 October 2018
Interactions with ibalizumab have been added to the website and HIV iChart app.
Ibalizumab is a monoclonal antibody which blocks HIV-1 from infecting CD4 cells by binding to domain 2 of CD4 and interfering with post-attachment steps required for viral entry. It is given by intravenous infusion every two weeks and must be used in combination with other antiretroviral drugs. No ...
Added: Wednesday 04 July 2018
Interactions with bictegravir/emtricitabine/tenofovir alafenamide are now included on the website, HIV i Chart app and printable charts. For ease of viewing on small screens, the listing appears as “Bictegravir/FTC/TAF”.
Bictegravir/emtricitabine/tenofovir alafenamide (Bictarvy®) is a fixed dose combination and is indicated as a complete regimen for the treatment of HIV-1 infection....
Added: Thursday 15 February 2018
Added: Wednesday 06 December 2017
All comedications have now been reassessed using the new interaction classification system which includes “yellow”. (Yellow interactions are likely to be of weak intensity and not requiring additional action or monitoring, or a dosage adjustment - click here for further details.)...
Added: Tuesday 21 November 2017
A further batch of comedications have been reassessed using the new interaction classification system (which includes “yellow”). This takes the total number of therapeutic drug classes updated to 26, and leaves just 13 classes still to update. The latest therapeutic classes to be updated are.
Added: Wednesday 15 November 2017
The first batch of comedications have been reassessed using the new interaction classification system which includes “yellow” (interactions likely to be of weak intensity and not requiring additional action or monitoring, or a dosage adjustment - click here for further details). Yellow interactions are now included fo...
Added: Wednesday 01 November 2017
Comedications within the Contraceptive and HRT class have been revised and the listing expanded to include various routes of administration and indications. The new listing now includes different hormonal contraceptive methods such as combined oral contraceptives (COC), progestogen only pills (POP), implants, vaginal rings, intra-uterine devices (IUD), patches and depot injections.
Added: Wednesday 25 October 2017
Over the next few months we will be expanding our interaction classification system to include a new “yellow” interaction, which will sit between the original green and amber classifications. Yellow interactions are likely to be of weak intensity and as such, additional action or monitoring, or a dosage adjustment is unlikely to be required. However, healthcare professionals should be aware of t...
Added: Tuesday 19 September 2017
Our guide to interactions with Hormone Therapy for gender transitioning has been updated to include triptorelin, testosterone enanthate or cypionate, and mixed testosterone esters. A new comment about the thromboembolic risk with conjugated estrogens has been added, as well as new review article in the reference section.
The update guided is found in the Interaction Cha...
Added: Tuesday 04 April 2017
The following drugs have been added to the comedication list, taking the number of comedications to over 650 drugs.
Added: Friday 25 November 2016
All versions (web, app, printable) of the interaction charts have been updated to include Odefsey®, a fixed-dose combination tablet containing rilpivirine, emtricitabine (FTC) and tenofovir alafenamide (TAF).
Interactions are listed under the abbreviation rilpivirine/FTC/TAF and, for the printable charts, the combination has been included as a NNRTI.
Added: Wednesday 19 October 2016
Nine new herbal preparations have been added to the comedication list. Note, for many of these preparations, pharmacokinetic studies have not been performed and the clinical effect has been estimated based on in vitro findings. In addition, it is unclear whether in vitro results with extracts from one part of the plant (e.g. leaf) are representative of other parts of the plants (e.g. root, bark)...
Added: Friday 05 August 2016
The web and app versions of the interaction charts have been updated to include Descovy®, a fixed-dose combination tablet containing emtricitabine (FTC) and tenofovir alafenamide (TAF). Interactions are listed under the abbreviation emtricitabine/TAF and the combination is classified as a nucleoside/tide analogue.
We are preparing updated printable charts to ...
Added: Tuesday 21 June 2016
Nos populaires tables d’interactions médicamenteuses entre antirétroviraux et différentes classes thérapeutiques sont maintenant aussi disponibles en français et peuvent être téléchargées depuis ce lien.
Les tables d’interactions en français ont été produites pour les classes thérapeutiques su...
Added: Wednesday 08 June 2016
Four new comedications have been added to the Anticoagulants, Antiplatelets and Fibrinolytic class. The new drugs are apixaban, dipyridamole, edoxaban and fondaparinux. All versions of the interaction charts (web, app and printable) have been updated with these new additions.
In related news, a new treatment selector for the class of Anticoagulants and Antiplatelets has been pr...
Added: Tuesday 07 June 2016
Added: Thursday 11 February 2016
Added: Monday 21 December 2015
Added: Tuesday 01 December 2015
Added: Tuesday 01 December 2015
Added: Friday 25 September 2015
Added: Tuesday 21 July 2015
Added: Monday 17 November 2014
Added: Thursday 30 October 2014
Cobicistat (Tybost®) as a single agent is licensed for the pharmacokinetic enhancement of atazanavir or darunavir. Interactions with cobicistat and comedications have now been added to web and app versions of the charts and, for ease of use, cobicistat can be found listed as protease inhibitor alongside atazanavir and darunavir. The printable versions of the charts will be updated shortly.
Added: Wednesday 22 October 2014
Added: Tuesday 22 July 2014
Added: Friday 30 May 2014
Added: Friday 14 February 2014
Added: Tuesday 15 October 2013
Added: Thursday 20 June 2013
Elvitegravir, an integrase inhibitor, was licensed in America during 2012 and is now licensed for use in Europe. Interactions with elvitegravir/cobicistat have been added to the website charts and the HIV iChart app - the printable charts will be updated in the next week. Elvitegravir is available only as a fixed dosed combination tablet (Stribild®) with cobicistat, emtricitabine and tenofovir. ...
Added: Tuesday 11 June 2013
Added: Friday 10 May 2013
Added: Thursday 28 March 2013
Added: Thursday 24 January 2013
Added: Thursday 06 December 2012
Added: Friday 09 November 2012
Added: Thursday 08 November 2012
We have produced a list of ARV formulations that can be used for patients who have difficulty swallowing. Further details (and a link to the document) can be found in the Interaction Charts / Treatment Selector section of this website.
Added: Thursday 10 May 2012
Added: Friday 13 January 2012
Added: Wednesday 19 October 2011
Added: Wednesday 17 August 2011
Added: Tuesday 16 August 2011
The pharmacokinetic fact sheets are now available in pdf format. As well as showing the structure and trade names for each drug, the fact sheets summarise key Information on pharmacokinetic parameters, metabolism and distribution. Fact sheets are currently available for the PIs, NRTIs, NNRTIs, entry/integrase inhibitors and hepatitis antivirals.
Added: Friday 29 July 2011
Added: Wednesday 13 July 2011
Two new anticoagulants have been added to the interaction charts - dabigatran (a direct thrombin inhibitor) and rivaroxaban (a direct Factor Xa inhibitor).
The online charts and iPhone and Android apps have been updated to include these new drugs. The printable version of the charts will be updated in the next few months.
Added: Friday 25 February 2011
Added: Friday 05 November 2010
There have been a few minor changes to the comedication classes on the charts and over 30 new drugs have been added. HIV-Charts2Go have been updated with these changes and the printable charts will be updated over the next few weeks.
Calcium channel antagonists are now named calcium channel blockers; hypertension drugs are included with heart failure agents and the class renamed ...
Added: Thursday 14 October 2010
Added: Wednesday 07 July 2010
The website is having to undergo essential maintenance on its infrastructure which will be completed by August. During this time user access to the site will not be affected, but it will mean that we are unable to update charts and other parts of the site. However, the latest news will continue to be added and email updates will be sent once a month.
Added: Friday 30 April 2010
The interaction database has been extensively updated to reflect changes in the European Summaries of Product Characteristics and US Prescribing Information. The printed version and PDA version of the charts have now been updated with all the web changes.
Added: Friday 30 April 2010
One of our projects for this year is to increase the number of WHO Essential Medicines listed on the charts. We have recently added a batch of new drugs which include some of these drugs, as well as other drugs added in response to queries we have received. The drugs listed below have been added to the web charts and the PDA charts (HIV-Charts2Go). Where possible, they will be added to the print...
Added: Tuesday 06 April 2010
The format of the interaction charts has been changed to make searching for interactions easier and to distinguish between those interactions for which data exists (“referenced interactions”) and those which are predicted based on routes of metabolism and elimination (“theoretical interactions”).
The search interface has been simplified so that there in now only one option. Previously ...
Added: Tuesday 06 October 2009
New fact sheets have been added to the Pharmacology Resources section of the website. These fact sheets contain information on the chemical nature and structure of a drug, its key pharmacokinetic parameters and its metabolism and distribution.
Facts sheets on elvitegravir and beviramat have been added to the Entry/Integrase/Maturation Inhibitors section.
A new section on Hep...
Added: Monday 28 September 2009
There are several additions to the interactions charts – both new drugs and a new class.
As well as introducing new drugs to existing classes, we have introduced a new class of drugs – Heart Failure Agents – which includes ACE inhibitors, angiotensin II receptor antagonists and diuretics. We have also expanded the steroid section to include not just the oral contraceptive steroids; no...
Added: Monday 30 March 2009
Many changes and additions have been made to the interactive interactions charts as a result of updates to SPCs and Prescribing Information. New versions of the printed charts and HIV-Charts2Go are available with these changes and additions.
Added: Thursday 06 November 2008
NEW - personalised, printable reports
We have launched a new feature for the interactive charts that allows you to create and save a summary of your chosen interactions in pdf format. Just make your drug selection in the usual way and, when the table of interactions is displayed, you will see a new option to generate a personalised report (please note that this feature is limited to ...
Added: Friday 03 October 2008
New Interactive Charts for Entry and Integrase Inhibitors
Interactive charts for Maraviroc and Raltegravir are now available. These charts are less extensive than the PI and NNRTI charts and have been compiled from the Summary of Product Characteristics, Prescribing Information, meeting abstracts and full papers. With a few exceptions, only drugs cited in these sources are listed. If...
Added: Thursday 04 September 2008
There have been some changes and additions to the Interaction Charts over the last few weeks.
On the Protease Inhibitor chart, amprenavir has been replaced by fosamprenavir. The interactions are essentially the same, apart from a few amber interactions that were due to the alcohol content of amprenavir oral solution and are not relevant for fosamprenavir.
On the NNRTI chart, ...
Added: Friday 29 August 2008
The smoking cessation drug varenicline (Champix®, Chantix®) has been added as a row to the interactive charts and will be included on the printed charts when they are next updated.
Drug interactions are not expected with varenicline as it has been shown in vitro not to inhibit or induce cytochrome P450 enzymes. Since less than 10% of varenicline is metabolised, CYP P450 inhibitors or ...
Added: Thursday 20 March 2008
Information on hormonal contraceptives is listed on the charts in the steroid section under ethinylestradiol and progesterone/progestogens. The information available is predominantly for daily oral contraceptives, but other routes and frequencies of administration are now available.
We have produced a chart which details the various forms of hormonal contraception and, for the newer form...
Added: Thursday 28 February 2008
The following drugs have been added as rows to the interaction charts:
Etravirine – new NNRTI
Maraviroc – new entry inhibitor
Elvitegravir – new integrase inhibitor
Raltegravir – new integrase inhibitor
A summary and description have been provided for those interactions where studies have been performed. If no studies have been performed, we have indicated a theor...
Added: Wednesday 28 November 2007
Interactions with maraviroc are now available on the website. Interactions with other HIV drugs have been added as new row to the existing charts.
Added: Wednesday 03 October 2007
Interactions with etravirine are now available on the website.
Etravirine (TMC125) is a next generation NNRTI that shows high intrinsic activity against both wild-type HIV-1 and strains with resistance-inducing mutations. Etravirine is metabolised by CYP3A4, CYP2C19 and UDP-glucuronyl transferase, and has been shown to induce CYP3A and inhibit CYP2C19 in vivo.
A substantial i...
Added: Wednesday 05 September 2007
Drug interaction summaries have now been added for all interactions where further information is available.
This new feature summarises key data from SPCs, Prescribing Information and published studies. Details of the direction and magnitude of the interaction and any management recommendations are given. These summaries will form the basis of the new PDA version of the charts which ...
Added: Thursday 21 June 2007
Darunavir (Prezista, TMC114) has now been added to the interaction charts in full. Currently only interactions detailed in the Summary of Product Characteristics or Prescribing Information are referenced. Details of interactions presented at meetings will be added in the next few months.
The other PIs have been updated also to reflect changes in made in the wording or data presente...
Added: Friday 01 June 2007
The NNRTI charts have been updated to reflect changes made in the wording or data presented in the most recent versions of the European Summaries of Product Characteristics and the US Prescribing Information.
New or amended interaction data have been added as follows:
Delavirdine Prescribing Information, updated from 2001 to February 2006 (carbamazepine, didanosine,...
Added: Friday 01 June 2007
Interaction charts with nucleoside and nucleotide analogues have now been completed and are available in interactive and printable formats. The NRTI charts feature a summary of the interaction as well as a full description (we are currently adding summaries to the PI and NNRTI charts).
The NRTI charts have been compiled from the Summaries of Product Characteristics, Prescribing Inform...
Added: Monday 12 March 2007
Interaction Charts - antimalarial drugs revised and expanded.
Added: Saturday 20 January 2007
Tipranavir (Aptivus), a non-peptidic protease inhibitor, was recently licensed in Europe (FDA approval was granted earlier this summer). We have now completed our evaluation of the literature and have added tipranavir interactions to the Interaction Charts.
Please note that as tipranavir (a powerful CYP3A and P-gp inducer) is coadministered with ritonavir (a potent inhibitor), predict...
Added: Tuesday 07 November 2006
Medscape Web Conference
Optimizing Antiretroviral Therapy for HIV: Key Pharmacologic Concerns.
Presenters: David Back, PhD, and Marta Boffito, MD, PhD
In this recent CME/Pharmacist CE program, David Back and Marta Boffito explain pharmacologic information of key importance to HIV clin...
Added: Friday 21 July 2006
The 7th International Workshop on Clinical Pharmacology of HIV Therapy was held this year in Lisbon. Several members of LHPG attended and presented data. Oral presentations were given by Laura Dickinson, Sara Gibbons and Saye Khoo, and poster presentations were given by Laura Else and Wai San Kwan.
Full details of all presentations from this meeting, will be available on www.hi...
Added: Wednesday 14 June 2006
The Drug Interaction Charts have been revised to include extra antimalarial drugs and additional information on existing drugs.
The following antimalarial drugs have been added to the interaction charts:
- Artemesinins (Artemether, Artesunate)
Further details on the nature of interactions with at...
Added: Friday 12 May 2006
Presentations from the recent meeting in Denver by members of the Liverpool HIV Pharmacology Group have now been added to the About Us section of this website. The posters are available as Acrobat pdf files and contain a link to the abstract from the Conference website.
Dr Andrew Owen presented the results of a proof of concept study to assess the impact of the G516T polymorphism on C...
Added: Friday 28 April 2006
The latest site update is a substantial redevelopment of the Interaction Charts. The new chart interface provides you with a greater level of flexibility, allowing you to select the specific interactions you need to review. This dynamically driven process offers detailed information on the predicted interactions of specified multiple drug combinations, and where appropriate, recommendations for ...
Added: Wednesday 08 March 2006